重组人促红素致抗EPO抗体介导的纯红细胞再生障碍性贫血1例  

A case of anti-EPO antibody-mediated pure red cell aplasia induced by recombinant human erythropoietin

作　　者：黄丽群 吕聪[1] 方俊海 卢光亮 黄小理 HUANG Li-qun;LV Cong;FANG Jun-hai;LU Guang-liang;HUANG Xiao-li(Department of Pharmacy,Minzu Hospital of Guangxi Zhuang Autonomous Region,Nanning 530001,China)

机构地区：[1]广西壮族自治区民族医院药学部,广西南宁530001

出　　处：《中国药物应用与监测》2023年第2期133-135,共3页Chinese Journal of Drug Application and Monitoring

基　　金：广西壮族自治区卫生健康委员会科研课题(Z20200779)。

摘　　要：1例33岁男性患者,2021年1月起开始规律血液透析,同时因贫血(Hb 77 g·L^(−1))开始予重组人促红素注射液(EPO,10000 IU,qw,ih)治疗,2021年10月3日患者出现2次晕厥并摔倒,查Hb 49 g·L^(−1),予停用EPO,并予输注红细胞、补铁等对症治疗,患者Hb未见明显回升,2021年11月24日检测抗EPO抗体和抗EPO中和抗体均为阳性,诊断为抗EPO抗体介导的纯红细胞再生障碍性贫血,予免疫抑制剂联合罗沙司他治疗后Hb上升至114 g·L^(−1),患者停止输血。A 33-year-old male patient received regular hemodialysis and recombinant human erythropoietin(EPO)injection(10000 IU,qw,ih)due to anemia(Hb 77 g·L^(−1))since January 2021.On October 3rd,2021,he experienced two episodes of syncope and fall and the hemoglobin suddenly dropped to 49 g·L^(−1).Recombinant human erythropoietin injection was discontinued,and symptomatic treatment including infusion of red blood cells and iron supplementation were given to him.But hemoglobin did not rise significantly.On November 24th,2021,EPO antibody and EPO neutralizing antibody were positive,and EPO antibody-mediated pure red cell aplasia was diagnosed.Hemoglobin increased to 114 g·L^(−1) after immunosuppressive therapy combined with roxadustat,and he got rid of blood transfusion.

关 键 词：重组人促红素 罗沙司他 纯红细胞再生障碍性贫血 药品不良反应 

分 类 号：R969.3[医药卫生—药理学] R973[医药卫生—药学]